SPOTLIGHT -
Atlanta-Glen Bradley will retire as chief executive officer of CIBA Vision in early 2003 after more than 30 years of service with affiliated Novartis Corp. companies.
SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease
(EyePod) From idea to impact: Navigating ophthalmic innovation
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy
EyePod: Modifier Gene Therapy: What is it?
Patients with dry eye suffer from worse sleep quality
Ophthalmic industry veteran Erin Schallhorn Powers joins Holland Foundation for Sight Restoration Board of Directors